低剂量里瓦洛克萨班:它是中国老年患者的安全替代品吗?
Yue Yu1, Wei Yang1, Wenyuan Li2
1Department of Geriatrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, P.R. China.
European journal of clinical pharmacology
|December 29, 2023
概括
低剂量里瓦罗克萨班 (10毫克) 显著降低了非膜性心房动 (NVAF) 患者的全因死亡率. 这项研究强调了与未服用抗凝血剂的患者相比,利瓦罗克萨班在NVAF患者的生存益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 非膜性心房动 (NVAF) 是一种常见的疾病,与中风和死亡风险增加有关.
- 里瓦罗克萨班是用于预防NVAF患者中风的广泛使用的抗凝剂.
- 了解不同剂量里瓦洛克萨班对死亡率的具体影响对于临床实践至关重要.
研究的目的:
- 调查每天一次服用10毫克里瓦罗克萨班与中国NVAF患者全因死亡率之间的关联.
- 为了比较使用里瓦洛克萨班治疗的NVAF患者与未接受抗凝药治疗的患者的死亡风险.
主要方法:
- 一项观察性研究涉及1131名来自西安嘉通大学第一附属医院的NVAF患者.
- 一年后续记录所有原因的死亡率和出血事件.
- 使用考克斯比例危险模型和卡普兰-梅尔分析进行统计分析.
主要成果:
- 该研究包括1131名患者:402名未接受治疗和729名接受里瓦洛克萨班治疗.
- 考克斯的比例危险分析显示,与没有抗凝药相比,里瓦洛克萨班 (10 mg:HR 0.14; 15 mg:HR 0.20; 20 mg:HR 0.22) 的死亡风险显著降低.
- 10 mg和15 mg的P值为<0.001和20 mg的P值为0.044,表明了统计学意义.
结论:
- 每天一次服用10毫克的里瓦罗克萨班在NVAF患者中显著降低了全因死亡率.
- 里瓦洛克萨班治疗,包括低剂量治疗方案,似乎为NVAF患者提供了生存益处.
- 这些发现支持使用里瓦洛克萨班来管理NVAF,特别是在老年人群中.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
702
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
702
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:11Renal Failure: Dose Adjustments
94
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
94
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K